Prothena Corporation EBIT per Share
The EBIT per Share of Prothena Corporation (PRTA) as of Oct 3, 2026 is -3.43 USD. In the previous year, EBIT per Share was -2.87 USD — a change of 19.37% (lower).
Get this data via API
Financial Data API
EBIT per Share
-3.43USD
YoY
19.37%
Last updated:
EBIT per Share of Prothena Corporation is 2026 -3.43 USD. EBIT per Share of Prothena Corporation was 2025 -2.87 USD. It decreases by 19.37% lower compared to the previous year.
The Prothena Corporation EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-3.56 USD
Jan 1, 2024
-2.87 USD
Jan 1, 2025
-3.43 USD
Jan 1, 2026 (e)
0.03 USD
Jan 1, 2027 (e)
-0.84 USD
Jan 1, 2028 (e)
-0.30 USD
Jan 1, 2029 (e)
-0.17 USD
Jan 1, 2030 (e)
2.35 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 2.35USD | -1,440.28% |
| est | -0.17USD | -41.81% |
| est | -0.30USD | -64.28% |
| est | -0.84USD | -3,346.53% |
| est | 0.03USD | -100.76% |
| -3.43USD | +19.37% | |
| -2.87USD | -19.31% | |
| -3.56USD | +46.05% | |
| -2.44USD | -257.86% | |
| 1.54USD | -154.67% | |
| -2.82USD | +31.47% | |
| -2.15USD | -46.10% | |
| -3.98USD | -2.68% | |
| -4.09USD | -11.19% | |
| -4.61USD | +82.32% | |
| -2.53USD | +941.48% | |
| -0.24USD | -87.15% | |
| -1.89USD | -32.07% | |
| -2.78USD | +33.17% | |
| -2.09USD | +203.64% | |
| -0.69USD | +731.25% | |
| -0.08USD | — |
Access this data via the Eulerpool API
Prothena Corporation Stock analysis
What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014.
Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions.
Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis.
A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017.
Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication.
Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases.
Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Prothena Corporation stock
EBIT per Share of Prothena Corporation is -3.43 USD in 2026.
EBIT per Share of Prothena Corporation changed from -2.87 USD to -3.43 USD, representing a 19.37% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Prothena Corporation
All Key Metrics — Prothena Corporation
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth